Didier Blaise
YOU?
Author Swipe
View article: Non‐T‐Depleted Haploidentical Transplantation Compared to Allogeneic Transplantation From Matched Siblings or Unrelated Donors in Patients With Secondary <scp>AML</scp> in First Complete Remission: A Study From the <scp>ALWP</scp> / <scp>EBMT</scp>
Non‐T‐Depleted Haploidentical Transplantation Compared to Allogeneic Transplantation From Matched Siblings or Unrelated Donors in Patients With Secondary <span>AML</span> in First Complete Remission: A Study From the <span>ALWP</span> / <span>EBMT</span> Open
Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative option for secondary acute myeloid leukemia (sAML). This study compared haploidentical donor (Haplo), matched sibling donor (MSD), and matched unrelated donor (MUD) HS…
View article: Allo-HCT outcomes for AML patients with NUP98 rearrangements: A study on behalf of the global committee, the ALWP and the PDWP of the EBMT
Allo-HCT outcomes for AML patients with NUP98 rearrangements: A study on behalf of the global committee, the ALWP and the PDWP of the EBMT Open
Background Acute myeloid leukemia (AML) with NUP98 rearrangements on chromosome 11p15 is a high-risk subtype with poor prognosis. Due to its rarity, the impact of allogeneic hematopoietic cell transplantation (allo-HCT) in these patients r…
View article: Phase 1 evaluation of the safety and efficacy of rapcabtagene autoleucel (YTB323) in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
Phase 1 evaluation of the safety and efficacy of rapcabtagene autoleucel (YTB323) in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) Open
Introduction: Most adult patients (pts) with r/r B-ALL die due to disease complications, indicating a need for more effective therapies. Rapcabtagene autoleucel is an innovative autologous next-generation CD19-directed chimeric antigen rec…
View article: Severe infections after CD19-directed chimeric antigen receptor T-cell therapy for Relapsed/Refractory large B-cell lymphoma, a retrospective real-life study from the DESCAR-T registry (LYSA)
Severe infections after CD19-directed chimeric antigen receptor T-cell therapy for Relapsed/Refractory large B-cell lymphoma, a retrospective real-life study from the DESCAR-T registry (LYSA) Open
Background CD19-directed chimeric antigen receptor (CAR) T-cell therapy has revolutionized the prognosis of relapsed/refractory large B-cell lymphoma (R/R LBCL). Infections are one of the major complications of this therapy. Few real-life …
View article: Allogeneic stem cell transplantation with post-transplantation cyclophosphamide in patients with acute myeloid leukemia achieving first complete remission after one versus two inductions: A study from the ALWP/EBMT
Allogeneic stem cell transplantation with post-transplantation cyclophosphamide in patients with acute myeloid leukemia achieving first complete remission after one versus two inductions: A study from the ALWP/EBMT Open
Background: Allogeneic transplantation (HSCT) is a curative therapeutic option for high-risk AML. The results of HSCT are in correlation with the disease status at transplant. Undergoing HSCT while in CR1 is an important prognostic factor.…
View article: Outcomes of primary graft failure in acute myeloid leukemia patients following unrelated transplantation with post-transplant cyclophosphamide: a study from the ALWP/EBMT
Outcomes of primary graft failure in acute myeloid leukemia patients following unrelated transplantation with post-transplant cyclophosphamide: a study from the ALWP/EBMT Open
We assessed pGF in 2497 AML patients undergoing HSCT from 8-10/10 HLA-matched UD with PTCy. pGF was defined as failure to achieve an ANC ≥ 0.5 × 10 9 /L by day +30 after HSCT. The day +30 cumulative incidence of ANC was 92.6% (95%CI: 91.5–…
View article: Impact of Donor Type on Outcomes After Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: A Study on Behalf of the Chronic Malignancies Working Party of the <scp>EBMT</scp>
Impact of Donor Type on Outcomes After Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: A Study on Behalf of the Chronic Malignancies Working Party of the <span>EBMT</span> Open
Selecting the optimal donor is crucial for optimizing results of allogeneic hematopoietic cell transplantation (allo‐HCT). We analyzed outcomes based on donor type in 2809 myelofibrosis (MF) patients undergoing first allo‐HCT between 2015 …
View article: Conditioning intensity in myelodysplastic patients aged ≥ 50 years undergoing allogeneic hematopoietic cell transplantation (allo-HCT): a study on behalf of the chronic malignancies working party of the EBMT
Conditioning intensity in myelodysplastic patients aged ≥ 50 years undergoing allogeneic hematopoietic cell transplantation (allo-HCT): a study on behalf of the chronic malignancies working party of the EBMT Open
Reduced intensity conditioning (RIC) is usually used for patients with myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (allo-HCT), particularly in the elderly or those with comorbidities. The impact …
View article: Graft‐versus‐host disease is not associated with reduced incidence of relapse following haploidentical stem cell transplantation with post‐transplant cyclophosphamide for acute lymphoblastic leukaemia: A study on behalf of the Acute Leukaemia Working Party of European Society for Blood and Marrow Transplantation
Graft‐versus‐host disease is not associated with reduced incidence of relapse following haploidentical stem cell transplantation with post‐transplant cyclophosphamide for acute lymphoblastic leukaemia: A study on behalf of the Acute Leukaemia Working Party of European Society for Blood and Marrow Transplantation Open
Summary The graft‐versus‐leukaemia effect (GVL) is closely associated with graft‐versus‐host disease (GVHD) after human leucocyte antigen (HLA)‐matched allogeneic stem‐cell transplantation (SCT) in acute lymphoblastic leukaemia (ALL). Howe…
View article: Impact of the addition of antithymocyte globulin to post‐transplantation cyclophosphamide in haploidentical transplantation with peripheral blood compared to post‐transplantation cyclophosphamide alone: A retrospective study on behalf of the Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation
Impact of the addition of antithymocyte globulin to post‐transplantation cyclophosphamide in haploidentical transplantation with peripheral blood compared to post‐transplantation cyclophosphamide alone: A retrospective study on behalf of the Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation Open
Summary In the setting of haploidentical haematopoietic cell transplantation (HCT), post‐transplant cyclophosphamide (PTCy) has dramatically reduced the incidence of graft‐versus‐host disease (GVHD) and non‐relapse mortality. To further re…
View article: Selection of unrelated donors for allogeneic transplantation using post-transplant cyclophosphamide in acute lymphoblastic leukemia: An analysis by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Selection of unrelated donors for allogeneic transplantation using post-transplant cyclophosphamide in acute lymphoblastic leukemia: An analysis by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation Open
Conflicting data exist on the impact of mismatched unrelated donor (MMUD) compared to matched unrelated donor (MUD) in hematopoietic cell transplantation (HCT) with post-transplant cyclophosphamide (PTCy), highlighting the need for disease…
View article: Older matched sibling donor vs young haploidentical donor for older patients with acute myeloid leukemia
Older matched sibling donor vs young haploidentical donor for older patients with acute myeloid leukemia Open
Selection of a suitable donor for allogeneic hematopoietic stem cell transplantation (allo-HCT) has mainly relied on HLA matching and, to date, a matched sibling donor (MSD) remains the first choice. However, patients with acute myeloid le…
View article: Superior <scp>GVHD</scp> ‐Free, Relapse‐Free Survival for Haploidentical Transplant With <scp>PTCy</scp> Than Matched Unrelated Donor for <scp>AML</scp> Patients Transplanted in Second Complete Remission: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Superior <span>GVHD</span> ‐Free, Relapse‐Free Survival for Haploidentical Transplant With <span>PTCy</span> Than Matched Unrelated Donor for <span>AML</span> Patients Transplanted in Second Complete Remission: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation Open
Donor preference for acute myeloid leukemia (AML) patients transplanted in second complete remission (CR2) remains unclear, and hematopoietic cell transplantation (HCT) with post‐transplant cyclophosphamide (PTCy) from a haploidentical don…
View article: Hematopoietic stem cell transplantation is effective in achieving long-term survival for post-aplastic anemia myeloid neoplasms: the EBMT Severe Aplastic Anemia Report
Hematopoietic stem cell transplantation is effective in achieving long-term survival for post-aplastic anemia myeloid neoplasms: the EBMT Severe Aplastic Anemia Report Open
Aplastic anemia (AA) transformation into myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) is associated with a dismal prognosis. Hematopoietic stem cell transplant offers the sole possibility of cure, but data on long-term s…
View article: TET2 mutation does not impact the prognosis of adult acute myeloid leukemia patients receiving a hematopoietic stem cell transplantation in first remission: similar outcome following matched sibling and unrelated <i>versus</i> haploidentical donor transplants in a multi-center retrospective analysis from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
TET2 mutation does not impact the prognosis of adult acute myeloid leukemia patients receiving a hematopoietic stem cell transplantation in first remission: similar outcome following matched sibling and unrelated <i>versus</i> haploidentical donor transplants in a multi-center retrospective analysis from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation Open
Not available.
View article: Table S2 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Table S2 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma Open
Multivariate cox regression analysis of different treatments for OS adjusting for baseline characteristics (ZUMA-2: n = 64, alloHCT: n = 272)
View article: Figure S1 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Figure S1 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma Open
Flow chart presenting inclusion and exclusion of patients used for final propensity score-matched analysis.
View article: Figure S2 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Figure S2 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma Open
Estimated conditional probabilities of receiving brexu-cel before (A) and after (B) matching.
View article: Table S4 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Table S4 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma Open
Multivariate cause-specific hazard regression analysis of different treatments for NRM in a competing risk setting adjusting for baseline characteristics (full case analysis, ZUMA-2: n = 64, alloHCT: n = 250).
View article: Table S6 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Table S6 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma Open
Acute and chronic Graft-versus-host-disease in the total alloHCT cohort based on full case analysis.
View article: Figure S4 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Figure S4 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma Open
Comparison of ZUMA-2 and alloHCT population for Overall survival (OS), Progression-free survival (PFS), Non-relapse mortality (NRM) and incidence of relapse (IR) in unmatched cohorts.
View article: Data from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Data from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma Open
Brexucabtagene autoleucel (brexu-cel) and allogeneic hematopoietic cell transplantation (alloHCT) are effective treatments for relapsed and refractory mantle cell lymphoma (r/r MCL), but the optimal choice remains unclear. We conducted an …